All In Biotech

Drug Trial Radar · NCT07935135

Study of CMP-002 in Participants With SYNGAP1-Related Disorder

A Double-blind, Randomized, Controlled, Multiple Ascending Dose Study of Intrathecally Administered CMP-002 in Participants With SYNGAP1-Related Disorder

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
CAMP4 Therapeutics CorporationIndustry
Sponsor type
Industry
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of CMP-002 in participants with SYNGAP1-related disorder.

Conditions

  • Nervous System Disease

Interventions

  • CMP-002Drug

    CMP-002 is an antisense oligonucleotide that will be administered by IT injection.

  • Sham-prickOther

    The sham-prick procedure involves no injection/puncture or penetration of the dura, but only a skin prick with a needle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of multiple doses of CMP-002: incidence of adverse events and changes from baseline in clinical laboratory resultsTime frame: Screening to Week 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Alemán

    Buenos Aires, Argentina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.